Saw palmetto
This article was originally published in The Tan Sheet
Executive Summary
Patients treated with botanical for six months had 32% decrease in dihydrotestosterone (DHT), a hormone associated with benign prostatic hyperplasia, researchers report in June Urology. Leonard Marks, UCLA School of Medicine, et al., randomized 44 men with symptomatic BPH to either 320 mg/day saw palmetto or placebo. Researchers took right and left mid-saggittal biopsy cores from each patient at baseline and after six months. Ongoing randomized, placebo-controlled trial funded by Urological Sciences Research Foundation and Alticor division Nutriline